Published in Blood Weekly, October 12th, 2006
Study 1: Acadesine is the first therapy proven to be effective for reducing the severity of acute postreperfusion myocardial infarction (MI) associated with coronary artery bypass graft (CABG) surgery.
According to a study from the United States, "The purpose of this study was to assess the safety and efficacy of the adenosine regulating agent (ARA) acadesine for reducing long-term mortality among patients with postreperfusion MI. No prospectively applied therapy exists that improves long-term survival after MI associated with CABG surgery-a robust model...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.